Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Novel biological therapies for managing non-Hodgkin lymphoma

Martin Dreyling • 5 Dec 2014
ASH 2014
Non-Hodgkin Lymphoma Lenalidomide

Prof Martin Dreyling (Ludwig-Maximilians University of Munich, Munich, Germany) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses novel biological therapies for the management of patients with non-Hodgkin lymphoma, including a phase II/III study of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

More from Martin Dreyling

TRIANGLE: ibrutinib with standard treatment or without autoHSCT in younger patients with MCL
7:56
TRIANGLE: ibrutinib with standard treatment or without autoHSCT in younger patients with MCL
Martin Dreyling • 10 Dec 2022

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals